|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Schering-Plough
|
|
gptkbp:acquisitionYear
|
2009
|
|
gptkbp:alsoKnownAs
|
MSD outside the United States and Canada
|
|
gptkbp:CEO
|
gptkb:Robert_M._Davis
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:divested
|
2021
Organon & Co.
|
|
gptkbp:ESRB_rating
|
gptkb:A_(MSCI,_2023)
|
|
gptkbp:founded
|
1891
|
|
gptkbp:founder
|
gptkb:George_Merck
|
|
gptkbp:headquartersLocation
|
gptkb:Kenilworth,_New_Jersey,_United_States
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:mainFieldOfActivity
|
gptkb:diabetes
animal health
infectious diseases
oncology
vaccines
vaccine development
cardiovascular diseases
pharmaceutical research
animal health products
|
|
gptkbp:marketCap
|
over $250 billion (2023)
|
|
gptkbp:notable_executive
|
gptkb:Robert_M._Davis
gptkb:Kenneth_C._Frazier
Roger M. Perlmutter
|
|
gptkbp:notableCase
|
gptkb:Vioxx_litigation
|
|
gptkbp:notableInvention
|
Gardasil patent
Keytruda patent
|
|
gptkbp:notableProduct
|
gptkb:Gardasil
gptkb:Isentress
gptkb:Januvia
gptkb:Keytruda
gptkb:Singulair
|
|
gptkbp:numberOfEmployees
|
~69,000 (2023)
|
|
gptkbp:parentCompany
|
none (independent)
|
|
gptkbp:predecessor
|
Merck & Co. (before 2009)
|
|
gptkbp:publiclyTraded
|
NYSE: MRK
|
|
gptkbp:relatedOrganization
|
gptkb:Merck_KGaA
|
|
gptkbp:revenue
|
$59.3 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:slogan
|
Inventing for Life
|
|
gptkbp:stockExchange
|
gptkb:Dow_Jones_Industrial_Average
gptkb:S&P_500
gptkb:S&P_100
|
|
gptkbp:stockSymbol
|
gptkb:MRK
|
|
gptkbp:subsidiary
|
gptkb:Merck_Research_Laboratories
gptkb:Merck_Animal_Health
|
|
gptkbp:website
|
https://www.merck.com/
|
|
gptkbp:bfsParent
|
gptkb:Schering-Plough_(2009)
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck & Co. (after 2009)
|